Premium
Occult hepatitis B virus infection in dialysis patients: a multicentre survey
Author(s) -
Fabrizi F.,
Messa P. G.,
Lunghi G.,
Aucella F.,
Bisegna S.,
Mangano S.,
Villa M.,
Barbisoni F.,
Rusconi E.,
Martin P.
Publication year - 2005
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2005.02501.x
Subject(s) - medicine , hepatitis b virus , hepatitis b , population , virology , hepatitis , hepatitis c virus , immunology , hepadnaviridae , virus , hbsag , gastroenterology , environmental health
Summary Background : The epidemiology and clinical significance of occult hepatitis B virus infection (serum hepatitis B surface antigen‐negative patients with detectable hepatitis B virus viraemia in serum) remains controversial with only limited information about its prevalence in patients on long‐term dialysis. Aim : To address the epidemiology of occult HBV infection in a large cohort of dialysis patients. Methods : We screened a large cohort ( n = 585) of Italian chronic dialysis patients; from this population, a group of hepatitis B virus surface antigen seronegative patients ( n = 213) was tested by Amplicor hepatitis B virus Monitor Test to detect hepatitis B virus viraemia (hepatitis B virus‐DNA) in serum. Results : Occult hepatitis B virus infection was absent (zero of 213 = 0%). Persistent hepatitis B virus surface antigen carriage was less frequent than anti‐hepatitis B virus core antibody (anti‐hepatitis B core antigen) seropositive status in this study group [1.88% (11 of 585) vs. 36% (216 of 585), P = 0.0001]. No dialysis patients seropositive for anti‐hepatitis B core antibody in serum (zero of 123 = 0%) had detectable hepatitis B virus‐DNA by polymerase chain reaction technology. No significant association between abnormal biochemical liver tests and serum anti‐hepatitis B core antibody was noted in our population. Nominal logistic regression analysis demonstrated an independent and significant relationship between anti‐HCV antibody and anti‐hepatitis B virus core antibody in serum (Wald chi‐square 16.06, P = 0.0001). The rate of seropositive patients for anti‐hepatitis B virus core antibody was higher among study patients than controls with normal renal function [36.9% (216 of 585) vs. 21.4% (59 of 275), P = 0.0001]; this difference partially persisted after correction for demographic parameters, and viral markers. Conclusion : In conclusion, occult hepatitis B virus was absent in our study group. Anti‐hepatitis B core antibody was significantly related to presence of anti‐HCV antibody supporting shared modes of transmission. Clinical studies based on molecular biology techniques provided with higher sensitivity are planned.